CASTLE BIOSCIENCES INC
For the period ended May 28, 2026. Filed Apr 8, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 28, 2026 · Filed Apr 8, 2026
Contents
Base Salaries
Base salaries serve to provide fixed cash compensation to our executive officers for performing their ongoing responsibilities. Base salaries for our executive officers are approved by the Compensation Committee upon employment, and are reviewed and adjusted, as appropriate, by the Compensation Committee on an annual basis, based on consideration of various factors, including:
The individual’s role and responsibilities;
Individual contribution and performance over the past year;
Labor market conditions;
Corporate performance; and
Salaries for similar positions within our industry and peer group.
Our Compensation Committee and, with respect to our CEO, the independent members of the Board, approved the following base salaries for our NEOs for fiscal 2025 after considering the factors above and our CEO’s feedback regarding the other NEOs. The NEOs’ salary increases were in line with the general policies implemented across the Company in setting pay increases.
| Named Executive Officer | 2024 Base Salary($) | 2025 Base Salary($) | Change(%) |
|---|---|---|---|
| Derek J. Maetzold | 715,572 | 751,350 | 5.0% |
| Frank Stokes | 500,042 | 522,544 | 4.5% |
| Tobin W. Juvenal | 506,415 | 529,204 | 4.5% |
| Kristen M. Oelschlager | 506,415 | 529,204 | 4.5% |
| 56 | Castle Biosciences 2026 Proxy Statement |
| Table of Contents | Compensation Discussion and Analysis |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.